Cholinergic central system, Alzheimer's disease, and anesthetics liaison: A vicious circle?

Journal of Alzheimer's Disease

Volumn 22, Issue SUPPL. 3, 2010, Pages

  Schifilliti, Daniela ^a   Santamaria, Letterio B ^a   Rosa, Giovanni ^b   Di Nino, Gianfranco ^c   Mandal, Pravat K ^d   Fodale, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Neurospectroscopy and Neuroimaging Laboratory   (India)

Author keywords

Alzheimer's disease; amyloid peptide; anesthesia; anesthetics; central cholinergic system; cholinergic receptors; liaison; neurodegenerative disorders; oligomerization

Indexed keywords

AMYLOID BETA PROTEIN; DESFLURANE; FENTANYL; HALOTHANE; ISOFLURANE; MORPHINE; NEOSTIGMINE; PHYSOSTIGMINE; PROPOFOL; REMIFENTANIL; SEVOFLURANE; THIOPENTAL;

ALZHEIMER DISEASE; AMNESIA; ANESTHESIA; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; HUMAN; NERVE DEGENERATION; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW;

EID: 78650475178     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101317     Document Type: Review

References (72)

1. Whitehouse PJ (1997) Genesis of Alzheimer's disease. Neurology 48, 2-7.
2. Francis PT, Palmer Am, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review progress. J Neurol Neurosurg Psychiatry 66, 137-147.
3. Musial A, Bajda M, Malawska B (2007) Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. CurrMedChem 14, 2654-2679.
4. Kar S, Slowikowski SP, Westaway D, Mount HT (2004) Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 29, 427-441.
5. Fodale V, Santamaria LB, Schifilliti D, Mandal PK (2010) Anaesthetics and postoperative cognitive dysfunction: a pathological mechanism mimicking Alzheimer's disease. Anaesthesia 65, 388-395.
6. Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306, 821-827.
7. Lander CJ, Lee JM (1998) Pharmacological drug treatment of Alzheimer's disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57, 719-731.
8. Blusztajn JK, Berse B (2000) The cholinergic neuronal phe-notype in Alzheimer's disease. Metab Brain Dis 15, 45-64.
9. Bartus RT, Dean RLIII, Beer B, Lipa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-417.
10. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br MedJ 2, 1457-1459.
11. Fodale V, Quattrone D, Trecroci C, Caminiti V, Santamaria LB (2006) Alzheimer's disease and anaesthesia: implications for the central cholinergic system. Br J Anaesth 97, 445-452.
12. Fernandez CR, Fields A, Richards T, Kaye AD (2003) Anesthetic considerations in patients with Alzheimer's disease. J Clin Anesth 15, 52-58.
13. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunet-ti N, Dalmonte E, Bianchin M, Mariani E (2005) Incidence and etiology of dementia in a large elderly Italian population. Neurology 64, 1525-1530.
14. Power AE (2004) Muscarinic cholinergic contribution to memory consolidation: with attention to involvement of the baso-lateral amygdala. CurrMed Chem 11, 987-996.
15. Westfall TC, Westfall DP (2008) Neurotrasmissione: sistema nervoso autonomo e sistema nervoso somativo. In Goodman & Oilman -Le basi farmacologiche della terapia, Brunton L, Parker K, Blumenthal D, Buxton I, eds. McGraw-Hill Italia, pp. 91-121.
16. Graham AJ, Ray MA, Perry EK, Jaros E, Perry RH, Volsen SG, Bose S, Evans N, Lindstrom J, Court JA (2003) Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J Chem Neuroanat 23, 97-113.
17. Perry E, Walker M, Grace J, Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22, 273-280.
18. Pratico C, Quartarone D, Lucanto T, Amato A, Penna O, Rosc-itano C, Fodale V (2005) Drugs of anesthesia on central cholin-ergic system may cause post-operative cognitive dysfunction and delirium. MedHypoth 65, 972-982.
19. Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99, 459-496.
20. Davies P, Maloney AJ (1976) Selective loss of central cholin-ergic neurons in Alzheimer's disease. Lancet 2, 1403.
21. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decar-boxylase activities in necropsy brain tissue. J Neurol Sci 34, 247-265.
22. Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterase in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4, 273-277.
23. Rylett RJ, Ball MJ, Colhoun EH (1983) Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex ofpatients with Alzheimer's disease. Brain Res 289, 169-175.
24. Nilsson L, Nordberg A, Hardy J, Wester P, Winblad B (1986) Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level. J Neural Transm 67, 275-285.
25. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease and senile dementia: loss ofneurons in the basal forebrain. Science 215, 1237-1239.
26. Levin ED, Damaj MJ, Glassco W, May EL, Martin BR (1999) Bridged nicotine, isonicotine and norisonicotine effects on working memory performance of rats in the radial-arm maze. Drug Dev Res 46, 107-111.
27. Levin ED, Toll K, Chang G (1996) Epibatidine, a potent nico-tinic agonists: effects on learning and memory in the radial-arm maze. Med Chem Res 6, 543-554.
28. Heishman SJ, Taylor RC, Henningfield JE (1994) Nicotine and smoking: a review of effects on human performance. Exp Clin Psychopharmacol 2, 335-395.
29. Savioz A, Leuba G, Vallet PG, Walzer C (2009) Contribution of neural networks to Alzheimer disease's progression. Brain Res Bull 80, 309-314.
30. Rosato-Siri M, Cattaneo A, Cherubini E (2006) Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice. J Physiol 576, 361-377.
31. Lee VM (2001) Abeta immunization: moving Abeta peptide from brain to blood. Proc Natl Acad Sci USA 98, 8931-8932.
32. Schubert P, Ogata T, Marchini C, Ferroni S (2001) Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target? Mech Ageing Dev 123, 47-57.
33. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766.
34. Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56, 321-339.
35. Clippingdale AB, Wade JD, Barrow CJ (2001) The amyloid-beta peptide and its role in Alzheimer's disease. J Pept Sci 7, 227-249.
36. Wisniewski T, Ghiso J, Frangione B (1997) Biology of A beta amyloid in Alzheimer's disease. Neurobiol Dis 4, 313-328. (Pubitemid 28018660)
37. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
38. Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, Grundke-Iqbal I (1998) Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J Neural Transm Suppl 53, 169-180.
39. Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, Octave JN, Pradier L, Touchet N, Tremp G (2001) Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp 67, 81-88.
40. Billingsley ML, Kincaid RL (1997) Regulated phosphoryla-tion and dephosphorylation of tau protein: effects on micro-tubule interaction, intracellular trafficking and neurodegener-ation. Biochem J 323, 577-591.
41. Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neu-rosci 21, 479-505.
42. Blusztajn JK, Berse B (2000) The cholinergic neuronal phe-notype in Alzheimer's disease. Metab Brain Dis 15, 45-64.
43. Nordberg A, Alafuzoff I, Winblad B (1992) Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 31, 103-111.
44. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B (1995) Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 9, 21-27.
45. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E (2001) Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49, 175-184.
46. Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, Perry E (2003) Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Olia 41, 207-211.
47. Lane RM, Kivipelto M, Greig NH (2004) Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27, 141-149.
48. Nordberg A (2000) Neuroprotection in Alzheimer's disease -new strategies for treatment. Neurotox Res 2, 157-165.
49. Lenzken SC, Lanni C, Govoni S, Lucchelli A, Schettini G, Racchi M (2007) Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact 165, 138-145.
50. Pavia J, De Ceballos ML, Sanchez de la Cuesta F (1998) Alzheimer's disease: relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins. Fund Clin Pharmacol 12, 473-481.
51. Fodale V, Santamaria LB (2003) The inhibition of central nicotinic nAch receptors is the possible cause of prolonged cognitive impairment after anesthesia. Anesth Analg 97, 1207.
52. Owman C, Fuxe K, Jason AM, Kahrstrom J (1989) Studies of protective actions of nicotinic on neuronal and vascular functions in rats: comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber system and the effect of a dopamine agonist. Prog Brain Res 79, 267-276.
53. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A (1997) Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 42, 159-163.
54. Woodruff-Park DS, Lander C, Geerts H (2002) Nicotinic cholinergic modulation: galantamine as a prototype. Cent Nerv Syst Drugs Rev 8, 405-426.
55. Mesulam M (2004) The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem 11, 43-49.
56. Ma J, Shen B, Stewart LS, Herrick IA, Leung LS (2002) The septohippocampal system participates in general anaesthesia. J Neurosci 22, 1-6.
57. Fodale V, Schifilliti D, Pratico C, Santamaria LB (2008) Remifentanil and the brain. Acta Anaesthesiol Scand 52, 319326.
58. Yoon MH, Choi JI, Jeong SW (2003) Antinociception of in-trathecal cholinesterase inhibitors and cholinergic receptors in rats. Acta Anaesthesiol Scand 47, 1079-1084.
59. Perouansky M (2008) General anesthetics and long-term neu-rotoxicity. Handb Exp Pharmacol 182, 143-157.
60. Perouansky M (2007) Liaisons dangereuses? General anaesthetics and long-term toxicity in the CNS. Eur J Anaesthesiol 24, 107-115.
61. Xie Z, Culley DJ, Dong Y, Zhang G, Zhang B, Moir RD, Frosch MP, Crosby G, Tanzi RE (2008) The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. Ann Neurol 64, 618-627.
62. Xie Z, Dong Y, Maeda U, Alfille P, Culley DJ, Crosby G, Tanzi RE (2006) The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology 104, 988-994.
63. Zhang B, Dong Y, Zhang G, Moir RD, Xia W, Yue Y, Tian M, Culley DJ, Crosby G, Tanzi RE, Xie Z (2008) The inhalation anesthetic desflurane induces caspase activation and increases amyloid beta protein levels under hypoxic conditions. J Biol Chem 283, 11866-11875.
64. Mandal PK, Pettegrew JW (2008) Abeta peptide interactions with isoflurane, propofol, thiopental and combined thiopental with halothane: a NMR study. Biochim Biophys Acta 1778, 2633-2639.
65. Bissette G (2009) Mini-forum: Roles of amyloid-beta and tau phosphorylation in neuronal repair and protection. J Alzheimers Dis 18, 369-370.
66. Mandal, PK, Bhavesh, NS, Chauhan, VS and Fodale, V (2010) NMR investigations of Aft peptide interactions with propofol at clinically relevant concentrations with and without aqueous halothane solution. J Alzheimer Dis 21, 1303-1309.
67. Mandal, PK, Simplaceanu, V and Fodale, V (2010) Intravenous Anesthetic Diazepam does not induce Amyloid beta-peptide Oligomerization but Diazepam Co-administered with Halothane Oligomerizes Amyloid Beta-peptide: An NMR study. J Alzheimer Dis 20, 127-134.
68. Mandal PK, Fodale V (2009) Smaller molecular-sized anesthetics oligomerize A/A peptide simulating Alzheimerfls disease: a relevant issue. Eur J Anesthesiol 46, 805-806.
69. Palotas M, Palotas A, Bjelik A, Pakaski M, Hugyecz M, Janka Z, Kalman J (2005) Effect of general anesthetics on amyloid precursor protein and mRNA levels in the rat brain. Neurochem Res 30, 1021-1026.
70. Liu Q, Wu J (2006) Neuronal nicotinic acetylcholine receptors serve as sensitive targets that mediate beta-amyloid neurotox-icity. Acta Pharmacologica Sinica 27, 1277-1286.
71. Rubio A, Perez M, Avila J (2006) Acetylcholine receptors and tau phosphorylation. Curr Mol Med 6, 423-428.
72. Hellstrom-Lindahl E (2000) Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 393, 255-263.